Ibogaine Side Effects:
What You Need to Know

Pre-Treatment Medical Review

Every patient submits a complete medical history, current medication list, and substance use timeline. Our physician reviews this before any commitment is made. Patients on contraindicated medications receive a supervised taper plan weeks before arrival.

12-Lead EKG & Bloodwork

Upon arrival, every patient undergoes a 12-lead EKG to establish baseline QTc interval. Patients with QTc above 450ms, structural heart abnormalities, or relevant cardiac history are excluded from ibogaine treatment. Complete bloodwork and liver panel confirm metabolic readiness.

Continuous Cardiac Monitoring

Throughout the entire 24-36 hour ibogaine session, patients are on continuous cardiac telemetry. Our medical team monitors QTc interval, heart rate, and rhythm in real time. Any deviation from expected parameters triggers immediate clinical intervention.

24/7 Physician Presence

A board-certified physician is on-site throughout every treatment session — not on call, not in the next building. Present in the facility, monitoring vitals, and prepared to intervene. Our nurse-to-patient ratio ensures individualized attention throughout.

Post-Treatment Monitoring

Cardiac monitoring continues for 24 hours after the acute phase. QTc interval is reassessed before the patient is cleared. Patients remain at the retreat for several days post-treatment under clinical observation before departure.

The most common side effects are nausea and vomiting (experienced by most patients within the first 2-4 hours), ataxia (impaired coordination lasting 12-24 hours), visual disturbances during the visionary phase, and fatigue that may persist for 1-3 days post-treatment. All of these are expected, temporary, and managed by our clinical team in real time.

Ibogaine causes QTc interval prolongation by blocking hERG potassium channels in the heart. In unsupervised settings without cardiac screening, this has contributed to documented fatalities. At MindScape, every patient undergoes pre-treatment 12-lead EKG screening, and patients with prolonged baseline QTc, structural heart disease, or relevant cardiac history are excluded from treatment. Continuous cardiac monitoring throughout the session ensures any QTc changes are detected and managed immediately.

The acute effects — including the visionary phase, nausea, and ataxia — typically resolve within 24-36 hours. Residual fatigue and mild emotional sensitivity may persist for 2-5 days as the body processes noribogaine. Most patients feel physically normal within one week, and many report increased energy and mood improvement starting around day 3-5 post-treatment.

Animal studies at extremely high doses (50 mg/kg and above — well above clinical doses) showed Purkinje cell degeneration in the cerebellum. At therapeutic doses used in clinical settings (typically 10-20 mg/kg), no neurotoxicity has been observed in human patients. MindScape uses carefully calibrated dosing based on body weight, medical history, and treatment goals.

Yes. A total of 58 ibogaine-associated emergencies and deaths have been documented in the medical literature, the vast majority occurring in unsupervised settings without cardiac screening, often involving concurrent opioid or stimulant use. In properly screened, medically supervised settings with continuous cardiac monitoring, the safety profile improves dramatically. MindScape has treated over 900 patients with zero medical complications.

Several medication classes are contraindicated with ibogaine, including SSRIs, SNRIs, MAOIs, methadone (requires extended taper), certain anti-arrhythmics, and medications that prolong QTc interval. Our medical team reviews every patient's medication history and manages safe discontinuation timelines before treatment. Never stop any medication without medical supervision.